
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Gatifloxacin, a newfluoroquinolone widely used for respiratory tract infections, was discoveredto have a spectrum of activity